UPDATE: Pacific Edge backtracks after European patent mix-up

UPDATE: Pacific Edge backtracks after European patent mix-up
(Updates with new company statements throughout, share price) By Paul McBeth Nov. 26 (BusinessDesk) - Pacific Edge, the non-invasive bladder cancer test developer, has quickly backtracked on an announcement that its Cxbladder had been granted a patent in Europe, when in fact its colorectal technology was given regulatory approval. The earlier announcement prompted a trading halt in Pacific Edge's shares, which had gained 4.9 percent to 85 cents before the halt, and held that increase when they resumed trading. The European Patent Of...